Personalized Medicine in Cardiovascular Diseases

다국어 초록 (Multilingual Abstract)

Personalized medicine is a novel medical model with all decisions and practices being tailored to individual patients in whatever ways possible. In the era of genomics, personalized medicine combines the genetic information for additional benefit in preventive and thera -peutic strategies. Personalized medicine may allow the physician to provide a better therapy for patients in terms of efficiency, safety and treatment length to reduce the associated costs. There was a remarkable growth in scientific publication on personalized medicine within the past few years in the cardiovascular field. However, so far, only very few cardiologists in the USA are incorporating personalized medi-cine into clinical treatment. We review the concepts, strengths, limitations and challenges of personalized medicine with a particular focus on cardiovascular diseases (CVDs). There are many challenges from both scientific and policy perspectives to personalized medicine, which can overcome them by comprehensive concept and understanding, clinical application, and evidence based practices. Individualized med-icine serves a pivotal role in the evolution of national and global healthcare reform, especially, in the CVDs fields. Ultimately, personalized medicine will affect the entire landscape of health care system in the near future.

참고문헌 (Reference)

1 Lewin J. Genetics, "Your Heart and Your Future" The American College of Cardiology

2 The National Forum for Heart Disease and Stroke Prevention, "Update to A Public Health Action Plan to Prevent Heart disease and Stroke" Nexus 2008

3 Voora D, "The pharmacogenetics of coumarin therapy" 6 : 503-513, 2005

4 Hamburg MA, "The path to personalized medicine" 363 : 301-304, 2010

5 Ku CS, "The discovery of human genetic variations and their use as disease markers: past, present and future" 55 : 403-415, 2010

6 Personalized Medicine Coalition, "The case for Personalized Medicine. 3rd ed"

7 Piquette-Miller M, "The art and science of personalized medicine" 81 : 311-315, 2007

8 Ganz P, "Testing endothelial vasomotor function: nitric oxide, a multipotent molecule" 108 : 2049-2053, 2003

9 McCrea CE, "Test-retest reliability of pulse amplitude tonometry measures of vascular endothelial function: implications for clinical trial design" 17 : 29-36, 2012

10 National Heart, Lung, and Blood Institute, "Summary Report" National Heart, Lung, and Blood Institute Working Group on Atheroprotective Genes

11 Topol EJ, "Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction" 104 : 2641-2644, 2001

12 Arnett DK, "Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group" 115 : 2878-2901, 2007

13 Aspinall MG, "Realizing the promise of personalized medicine" 85 : 108-165, 2007

14 Mateos-Cáceres PJ, "Proteomic analysis of plasma from patients during an acute coronary syndrome" 44 : 1578-1583, 2004

15 Parguiña AF, "Proteins involved in platelet signaling are differentially regulated in acute coronary syndrome: a proteomic study" 5 : e13404-, 2010

16 Bates S, "Progress towards personalized medicine" 15 : 115-120, 2010

17 US President’s Council of Advisors on Science and Technology, "Priorities for Personalized Medicine" Executive Office of the President of United States 2008

18 Roden DM, "Pharmacogenomics: challenges and opportunities" 145 : 749-757, 2006

19 Aquilante C, "Pharmacogenomics: The Promise of Personalized Medicine" University of Colorado 2007

20 Degoma EM, "Personalized vascular medicine: individualizing drug therapy" 16 : 391-404, 2011

21 Chan IS, "Personalized medicine: progress and promise" 12 : 217-244, 2011

22 Lunshof JE, "Personalized medicine: decades away?" 7 : 237-241, 2006

23 Hudson TJ, "Personalized medicine: a transformative approach is needed" 180 : 911-913, 2009

24 Bonter K, "Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine" 1 : e000110-, 2011

25 Lloyd-Jones DM, "Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring" 291 : 2204-2211, 2004

26 Fox CS, "Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring" 291 : 2851-2855, 2004

27 Genentech USA Inc, "PERSONALIZED MEDICINE: Identifying the Appropriate Patient Through Biomarkers in Oncology" 20 (20): 2011

28 Ruben RJ, "Otitis media: the application of personalized medicine" 145 : 707-712, 2011

29 Califf RM, "Organizational improvements to enhance modern clinical epidemiology" 300 : 2300-2302, 2008

30 Deng MC, "Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling" 6 : 150-160, 2006

31 Bristow M, "New Frontiers in Personalized Medicine: Cardiovascular Research and Clinical Care, In Personalized Medicine Coalition" The George Washington University 2011

32 Sabatine MS, "Metabolomic identification of novel biomarkers of myocardial ischemia" 112 : 3868-3875, 2005

33 Shapiro SD, "Merging personalized medicine and biology of aging in chronic obstructive pulmonary disease" 184 : 864-866, 2011

34 McCarthy JJ, "Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes" 41 : 334-341, 2004

35 The International HapMap Consortium, "International HapMap Project"

36 Weinshilboum R, "Inheritance and drug response" 348 : 529-537, 2003

37 Weinshilboum R, "Inheritance and drug response" 348 : 529-537, 2003

38 Kongkaew C, "Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies" 42 : 1017-1025, 2008

39 Peyser PA, "Heritability of coronary artery calcium quantity measured by electron beam computed tomography in asymptomatic adults" 106 : 304-308, 2002

40 Collins F, "Has the revolution arrived?" 464 : 674-675, 2010

41 Kasper DL, "Harrison’s principles of internal medicine. 17th ed" McGraw-Hill Medical Publishing Division 2008

42 Schwartz PJ, "Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias" 103 : 89-95, 2001

43 Manace LC, "Genomics of cardiovascular disease" 76 : 613-623, 2009

44 Guttmacher AE, "Genomic medicine--a primer" 347 : 1512-1520, 2002

45 Ginsburg GS, "Genomic and personalized medicine: foundations and applications" 154 : 277-287, 2009

46 Samani NJ, "Genomewide association analysis of coronary artery disease" 357 : 443-453, 2007

47 Manolio TA, "Genetics of ultrasonographic carotid atherosclerosis" 24 : 1567-1577, 2004

48 Tester DJ, "Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice" 123 : 1021-1037, 2011

49 Marenberg ME, "Genetic susceptibility to death from coronary heart disease in a study of twins" 330 : 1041-1046, 1994

50 Nordlie MA, "Genetic contributors toward increased risk for ischemic heart disease" 39 : 667-679, 2005

51 Kardia SL, "Family-centered approaches to understanding and preventing coronary heart disease" 24 : 143-151, 2003

52 Arnar DO, "Familial aggregation of atrial fibrillation in Iceland" 27 : 708-712, 2006

53 US Food and Drug Administration, "FDA approves updated warfarin (Coumadin®) prescribing information"

54 O’Donnell CJ, "Evidence for heritability of abdominal aortic calcific deposits in the Framingham Heart Study" 106 : 337-341, 2002

55 Wright CF, "Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how?" 127 : 125-134, 2010

56 Lerman A, "Endothelial function: cardiac events" 111 : 363-368, 2005

57 Deanfield JE, "Endothelial function and dysfunction: testing and clinical relevance" 115 : 1285-1295, 2007

58 Johnson JA, "Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges" 13 : 525-534, 2003

59 Zineh I, "Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs" 40 : 639-644, 2006

60 Thomas M, "Desperately seeking microRNA targets" 17 : 1169-1174, 2010

61 Hamburg NM, "Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study" 117 : 2467-2474, 2008

62 Rubinshtein R, "Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score" 31 : 936-942, 2010

63 Shimizu W, "Clinical impact of genetic studies in lethal inherited cardiac arrhythmias" 72 : 1926-1936, 2008

64 Spear BB, "Clinical application of pharmacogenetics" 7 : 201-204, 2001

65 O’Donnell CJ, "Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: the beginning of an era" 1 : 51-57, 2008

66 Kramer BS, "Cancer screening: the clash of science and intuition" 60 : 125-137, 2009

67 Biomarkers Definitions Working Group, "Biomarkers and surrogate endpoints: preferred definitions and conceptual framework" 69 : 89-95, 2001

68 Aithal GP, "Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications" 353 : 717-719, 1999

69 Lee DS, "Association of parental heart failure with risk of heart failure in offspring" 355 : 138-147, 2006

70 Rubinshtein R, "Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events" 31 : 1142-1148, 2010

71 Helgadottir A, "A common variant on chromosome 9p21 affects the risk of myocardial infarction" 316 : 1491-1493, 2007

72 McPherson R, "A common allele on chromosome 9 associated with coronary heart disease" 316 : 1488-1491, 2007

73 Monroe JB, "A coalition to drive personalized medicine forward" 1 : 9-13, 2004

74 Jørgensen JT, "A challenging drug development process in the era of personalized medicine" 16 : 891-897, 2011

75 Hindorff LA, "A catalog of published genome-wide association studies"

76 Manolio TA, "A HapMap harvest of insights into the genetics of common disease" 118 : 1590-1605, 2008